Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

(MEASURE Trial)

Recruiting at 17 trial locations

Overseen By Study Inbox

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Center for International Blood and Marrow Transplant Research

Disqualifiers: Acute promyelocytic leukemia, prior alloHCT

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

303 Participants Needed

Trial Summary

What is the purpose of this trial?

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Research Team

Christopher Hourigan, DM, D.Phil.

Principal Investigator

Virginia Polytechnic Institute and State University

Jeffrey Auletta, MD

Principal Investigator

National Marrow Donor Program

Eligibility Criteria

Inclusion Criteria

Complete remission (CR) definition per local institutional criteria

Has specimen from time of AML diagnosis available

Provision of signed and dated informed consent form

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Transplantation

Participants undergo allogeneic hematopoietic cell transplantation (alloHCT)

1 week

Post-Transplant Monitoring

Participants provide blood samples at months 1-6, 9, 12, 15, and 18 post-transplant for MRD testing

18 months

Multiple visits for blood sample collection

Follow-up

Participants are monitored for relapse and survival outcomes

3 years

Treatment Details

Interventions

• Prospective determination of the clinical utility of measurable residual disease (MRD) testing

Participant Groups

Group I: Adult patients with AML in complete remission undergoing alloHCT Experimental Treatment 1 Intervention

Adult patients with AML in complete remission undergoing alloHCT

Who Is Running the Clinical Trial?

Center for International Blood and Marrow Transplant Research

Lead Sponsor

Trials

40

Recruited

200,190,000+

National Marrow Donor Program

Collaborator

Trials

63

Recruited

202,000+